Felicia Schwartz, Wall Street Journal

Felicia Schwartz

Wall Street Journal

Washington, DC, United States

Contact Felicia

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • Wall Street Journal
Past:
  • Moneyish
  • Cashay

Recent articles by Felicia:

FDA Aims for Quick Review of Omicron Vaccines and Drugs

The agency and drugmakers are working to develop testing and manufacturing guidelines in case they are needed for a speedy fight against the new Covid-19 variant. → Read More

Covid-19 Boosters Become Available to All Adults Across Several States, Cities

To guard against a winter surge, several states and cities are expanding eligibility for Covid-19 booster shots to all adults, though the federal government recommends only high-risk people get the doses. → Read More

Biogen Investigates Death of Aduhelm Patient

The company is exploring whether the death of the 75-year-old, who experienced brain swelling, is linked to use of the Alzheimer’s drug. → Read More

As Covid-19 Vaccines Approach for Young Kids, Many Parents Plan to Wait

Many want to wait and see, worried the shots were developed too quickly and could have unexpected side effects, concerns that doctors say are unfounded. → Read More

Moderna Confirms FDA Delayed Covid-19 Vaccine in Adolescents to Review Myocarditis Risk

The drugmaker also said it would delay seeking authorization of its vaccine for younger children pending the outcome of the FDA’s review. → Read More

CDC Advisers Back Moderna, J&J Covid-19 Booster Shots

The panel also supports mixing-and-matching approach; now it is up to the CDC director to sign off on the extra doses. → Read More

FDA may soon approve mixing and matching COVID booster shots

The Food and Drug Administration is moving to soon allow people to receive booster shots that are different from their first COVID-19 vaccine doses, people... → Read More

FDA Delays Moderna Covid-19 Vaccine for Adolescents to Review Rare Myocarditis Side Effect

Moderna asked the Food and Drug Administration in June to expand use of the company’s Covid-19 vaccine to 12-to-17-year-olds, but the agency has held off while it looks into the risk of myocarditis, a rare heart condition. → Read More

FDA Advisors to Consider Moderna Covid-19 Booster Shot

Vaccine experts advising the FDA are meeting Thursday to review the data for a booster of Moderna’s Covid-19 vaccine, then make a recommendation to the agency on authorizing the extra dose. → Read More

Fully Vaccinated and Had Covid-19? No Rush for a Booster Shot, Experts Say

Thinking about getting a Covid-19 booster shot? Millions of Americans who got the Pfizer-BioNTech vaccine are now eligible—but if they are fully vaccinated and had a real-world infection, they probably don’t need it. → Read More

CDC Panel Recommends Pfizer Covid-19 Boosters for Seniors, Certain Adults With Underlying Medical Conditions

The recommendations were largely in line with the Food and Drug Administration’s authorization but diverged on giving the extra shot to people whose use was FDA-authorized: adults who work or live in places that put them at high risk of getting infected or transmitting to others. → Read More

J&J Says Covid-19 Vaccine Booster Two Months After First Shot Increases Protection

Johnson & Johnson said a booster dose of its Covid-19 vaccine administered two months after the first shot increased protection against symptomatic illness in trial participants. → Read More

Flu Season 2021: What to Know About Flu Vaccine as Covid-19 Pandemic Continues

Some health experts are warning of a possible “twindemic” of flu and coronavirus infections. Here’s how to protect yourself. → Read More

This Flu Season Is Expected to Be Worse Than the Last One, Threatening Hospitals Strained by Delta

The coming flu season is on track to be much worse than the last cycle, according to health experts, who fear an influx of cases could further strain hospitals already overwhelmed by the Delta surge. → Read More

Use of Antiparasitic Drug Ivermectin Against Covid-19 Prompts Warnings

Prescriptions have surged for antiparasitic drug ivermectin, including veterinary versions; the FDA and CDC issue health advisories, citing a surge in reports of severe illness resulting from misuse. → Read More

J&J Says Covid-19 Booster Shots After Eight Months Supported by Data

Booster recipients showed a ninefold increase in antibody levels compared with one month after the first dose, researchers have found. → Read More

As Covid-19 Boosters Loom, Pfizer and Moderna Expected to See Billions More in Sales

The two makers of messenger RNA vaccines are on track to notch billions more in sales than previously expected, as new booster-shot strategies and concerns about the Delta variant increase demand, and the companies raise prices. → Read More

Ask WSJ: What You Need to Know About the Covid-19 Vaccine Boosters

On Wednesday, the Biden administration called for a third shot for adults who are fully vaccinated with the two-shot regimen from Pfizer Inc. and its partner BioNTech or Moderna Inc. This follows the U.S. Food and Drug Administration’s authorization last week of booster shots for those with compromised immune systems. Join Wall Street Journal editor Jonathan Rockoff in conversation with… → Read More

J&J Vaccine Highly Effective Against Delta Variant in South African Trial

The results from the trial of nearly 480,000 healthcare workers mark the first real world test of J&J’s single dose vaccine against the Delta variant. → Read More

Novavax Delays Seeking U.S. Regulatory Approval for Covid-19 Vaccine

Novavax said it would delay seeking U.S. emergency authorization for its Covid-19 vaccine until the fourth quarter as it works to complete the manufacturing portion of its application. → Read More